Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Despite growing evidence, variability in exposure assessment and potential biases continue to limit causal inference, emphasizing the need for integrative molecular-epidemiologic approaches to better identify vulnerable subgroups and refine quantitative risk estimates
NCT04847557) seeks to evaluate the effect of tirzepatide (is a dual agonist for the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors) over 52 weeks in 700 patients with heart failure with preserved ejection fraction (HFpEF) and obesity
R.HornsteinM
Who should consult before using it
10.14309/01.ajg.0000594772.87672.64 32 FernandezA
Some competitors with monthly billing give you more flexibility to pause or cancel
US$ 23.39
US$ 27.38
US$ 24.20
US$ 22.80
US$ 23.22
